Identity graph
D3 Bio headquarters, locations and relationships
- Legal name
- D3 Bio, Inc.
- Industry
- Biotechnology
- Founded
- 2020
- Website
- d3bio.com
- LinkedIn profile for D3 Bio
D3 Bio office locations
| City | State / region | Country | Type |
|---|---|---|---|
| Binhu | Jiangsu | China | Headquarters |
- Parent company
- No parent company recorded in GraphIQ.ai.
Verified from public filings, company websites and news · Methodology
Open in GraphIQ.aiMore D3 Bio data in GraphIQ.ai
This page shows the public record. Sign in with a work email to open the rest of the entity.
-
Technographics (available after sign-in)
Software, cloud and infrastructure in use.
-
Firmographics (available after sign-in)
Revenue, headcount, growth and industry codes.
-
Capabilities (available after sign-in)
Products, services and certifications.
-
News (available after sign-in)
Recent coverage and signals, resolved to the entity.
-
And more (available after sign-in)
Subsidiaries, people and lookalike companies.
Who uses the D3 Bio entity
-
Revenue and GTM teams
Territories, enrichment and account expansion on one resolved account.
RevOps Sales & marketing -
Industry and supply chain
Suppliers, sites and partners mapped to the right legal entity.
Industry -
Private equity and investors
Corporate family, comparable companies and deal sourcing.
Private equity -
Government and public sector
Supplier vetting, ownership and jurisdiction checks against one verified entity.
Government -
Developers and AI agents
The entity and its relationships through the REST API and MCP server.
Developers
About D3 Bio
D3 Bio is headquartered in Binhu, Jiangsu, China. Founded in 2020, the company employs approximately 26 people worldwide.
Where is D3 Bio's main office?
D3 Bio's main headquarters office is located at 88 Meiliang Road Mashan Street Room 324, Binhu, Jiangsu 214000, China. This is the company's primary corporate address.
What does D3 Bio do?
D3 Bio is a globally focused biotechnology company focusing on developing and registration of innovative medicines in oncology and immunology. At D3 Bio, their new medicine development approach is fundamentally differentiated. They do not just only start with science in the lab. First, they pinpoint the greatest unmet patient and market needs - where existing standard-of-care approaches yield unsatisfactory clinical outcomes. Then they take those insights into lab to guide the identification of fit for purpose science and technology, and define their drug development path. D3 Bio R&D programs are also designed to create a structure, which would enable us to create a robust portfolio and identify assets carrying “back-bone” property for developing future therapies in multiple indications. Their portfolio will include assets from internal effort as well as assets in-licensed in pre-clinical or clinical-stage investigational compounds. This cycle of innovation is at the heart of D3 Bio. In fact, it underlies their name: Development leading to Discovery that then leads back to more Development, or D3 Bio.” D3 Bio is backed by a syndicate of world-class investors whose support underscores their belief in the promise of the Company. Major investors include Boyu Capital, Matrix Partners China, Sequoia Capital China, Temasek, and WuXi AppTec's Corporate Venture Fund.
One entity, every stage
Put D3 Bio to work across your revenue bowtie
- Target Define the market Build the account list from companies shaped like your best customers, D3 Bio included. Fingerprint search
- Cover Plan territories D3 Bio resolves to one account, so it lands in one territory, once. Territory planning
- Engage Act on timing Leadership changes, funding and M&A arrive linked to the account, not a loose headline. Signal monitoring
- Convert Close on a resolved record Inbound and closed-won attach to one CRM record, with no duplicates to merge. CRM enrichment
- Retain Ground every answer Customer teams and AI agents answer from the same entity, with a source and a date. AI agent data layer
- Expand Find the next buyer inside Follow subsidiaries and divisions to the next team that can buy. Account expansion
About the source
What is GraphIQ.ai?
A B2B identity graph. It resolves each organization into one verified entity and maps its parent and subsidiaries, employees, competitors and news signals. Revenue teams use it in the product; AI agents query it through the REST API and MCP server.
POST/api/v2/organizations/search
D3 Bio: frequently asked questions
Where is D3 Bio headquarters?
88 Meiliang Road Mashan Street Room 324, Binhu, Jiangsu 214000, China.
When was D3 Bio founded?
2020.
How many employees does D3 Bio have?
About 26, as of October 2026 (GraphIQ.ai estimate).
Questions about GraphIQ.ai
Is GraphIQ.ai a list of companies like a spreadsheet?
No. Each organization resolves to one verified entity linked to its parent, subsidiaries, people and signals, so D3 Bio here is the same D3 Bio in your CRM, territory plan and agent answers.
Where does this D3 Bio data come from?
Public filings, company websites and news, resolved to one entity and continuously updated.